SCHEMBL17110437

SCHEMBL17110437

Cc1c(C(=O)Cl)cnn1[C@H]1CC[C@](C)(C(C)=O)CC1

nearest known ligand 0.38

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 3/20 0.38
MGLL Q99685 1/20 0.32
DRD2 P14416 1/20 0.30
DRD4 P21917 1/20 0.30
DRD3 P35462 1/20 0.30
AURKA O14965 1/20 0.30
CDK1 P06493 1/20 0.30
AURKB Q96GD4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17110187 0.88 TRPV4 (0.38) TRPV4MGLLDRD2DRD4DRD3
SCHEMBL31433034 0.84 MGLL (0.38) TRPV4MGLLDRD2DRD4DRD3
SCHEMBL17110424 0.84 PRMT1 (0.37) TRPV4
SCHEMBL17110205 0.79 LRRK2 (0.34) TRPV4AURKACDK1AURKB
SCHEMBL16654536 0.77 SPR (0.38) TRPV4
SCHEMBL17110178 0.77 PLAT (0.40) DRD2DRD4DRD3
SCHEMBL17110206 0.76 LMNA (0.40)
SCHEMBL17110464 0.74 SPR (0.33) TRPV4MGLL
SCHEMBL17110204 0.73 ALDH1A1 (0.37) TRPV4
SCHEMBL17110207 0.73 LMNA (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365522-B2 Pyrazole amide derivative AMGEN INC. (US) 2016-06-14 US disclosed
US-20150266824-A1 Pyrazole Amide Derivative TEIJIN LIMITED (JP) 2015-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266824-A1 Pyrazole Amide Derivative RORC, RORB, RORA TRPV4 1692/4885MGLL 4455/4885DRD2 3833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.